- Home
- IMCC vs LIXT Comparison
IMCC vs LIXT Comparison
Compare IMCC & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- LIXT
- Stock Information
- Founded
- IMCC 1980
- LIXT 2005
- Country
- IMCC Israel
- LIXT United States
- Employees
- IMCC N/A
- LIXT N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- LIXT Health Care
- Exchange
- IMCC Nasdaq
- LIXT Nasdaq
- Market Cap
- IMCC 5.0M
- LIXT 4.2M
- IPO Year
- IMCC N/A
- LIXT N/A
- Fundamental
- Price
- IMCC $2.81
- LIXT $1.62
- Analyst Decision
- IMCC
- LIXT
- Analyst Count
- IMCC 0
- LIXT 0
- Target Price
- IMCC N/A
- LIXT N/A
- AVG Volume (30 Days)
- IMCC 27.2K
- LIXT 1.8M
- Earning Date
- IMCC 11-14-2024
- LIXT 11-12-2024
- Dividend Yield
- IMCC N/A
- LIXT N/A
- EPS Growth
- IMCC N/A
- LIXT N/A
- EPS
- IMCC N/A
- LIXT N/A
- Revenue
- IMCC $38,042,859.00
- LIXT N/A
- Revenue This Year
- IMCC $22.59
- LIXT N/A
- Revenue Next Year
- IMCC $20.53
- LIXT N/A
- P/E Ratio
- IMCC N/A
- LIXT N/A
- Revenue Growth
- IMCC N/A
- LIXT N/A
- 52 Week Low
- IMCC $1.13
- LIXT $1.31
- 52 Week High
- IMCC $8.10
- LIXT $4.42
- Technical
- Relative Strength Index (RSI)
- IMCC 71.25
- LIXT 43.04
- Support Level
- IMCC $1.84
- LIXT $1.56
- Resistance Level
- IMCC $3.34
- LIXT $1.87
- Average True Range (ATR)
- IMCC 0.26
- LIXT 0.23
- MACD
- IMCC 0.10
- LIXT -0.03
- Stochastic Oscillator
- IMCC 64.78
- LIXT 8.33
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.